Form 4: Ligand Pharmaceuticals Director Jason Aryeh Reports Significant Equity Grant

Ligand Pharmaceuticals Inc. Director and 10% owner Jason Aryeh reported the acquisition of 1,209 restricted stock units and 5,783 non-qualified stock options as part of a Board grant on June 6, 2025.

Summary

• Jason Aryeh, a Director and 10% owner of Ligand Pharmaceuticals Inc. (LGND), reported changes in his beneficial ownership through a Form 4 filing.
• On June 6, 2025, Mr. Aryeh was granted 1,209 restricted stock units (RSUs) and 5,783 non-qualified stock options.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock, granted at a price of $0.0.
• The non-qualified stock options have an exercise price of $105.99 and an expiration date of June 6, 2035, also granted at a price of $0.0.
• Both the RSUs and stock options were granted by the Company's Board of Directors at their annual meeting on June 6, 2025.
• These grants will fully vest on the earlier of the date of the next annual meeting of the Company stockholders following the grant date or the first anniversary of the grant date.
• Following these transactions, Mr. Aryeh's beneficial ownership includes 79,289 shares of common stock directly, 51,594 shares indirectly through certain funds managed by JALAA Equities, LP and JLV Investments, LP and affiliates, and 5,025 shares indirectly by Trust, totaling 135,908 shares of common stock. He also directly owns 5,783 non-qualified stock options.

Sentiment

Score: 7

Explanation: The grant of equity to a director and 10% owner is generally a positive signal, indicating alignment of interests and confidence in the company's future. While it represents a compensation expense, it's a standard practice for incentivizing key personnel.

Positives

• The grant of restricted stock units and stock options to a director aligns management and director interests with those of shareholders, incentivizing long-term performance.
• The acquisition of additional equity by a 10% owner and director can be seen as a sign of confidence in the company's future prospects.

Negatives

• The issuance of new equity upon vesting and exercise could lead to minor dilution for existing shareholders, though this is a standard practice for executive and director compensation.

Future Outlook

The restricted stock units and stock options granted to Director Jason Aryeh are subject to a vesting schedule, which will occur on the earlier of the next annual meeting of stockholders following the grant date or the first anniversary of the grant date. This indicates a future commitment and potential increase in the director's direct beneficial ownership.

Management Comments

• The grants were "Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025."

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically an equity grant to a director. Such grants are common practice across industries, including the pharmaceutical sector, to incentivize and align the interests of directors and executives with shareholders. It does not provide information on broader industry trends or competitive landscape.

Comparison to Industry Standards

• Equity grants to directors and executives, including restricted stock units and stock options, are standard compensation practices across publicly traded companies, including those in the pharmaceutical industry.
• The vesting schedule (earlier of next annual meeting or one year) is a common approach to ensure retention and align long-term interests.
• The exercise price of $105.99 for the options is likely the market price on the grant date, which is standard for non-qualified stock options.

Corporate Governance

Related Party Transactions

• Jason Aryeh's indirect beneficial ownership of 51,594 shares is through certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates, where Mr. Aryeh is the General Partner or a partner. This constitutes a related party transaction as it involves entities controlled or significantly influenced by the reporting person.

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting and exercise of equity, but also increased alignment of a significant director's interests with shareholder value.
• Employees: No direct impact mentioned for general employees.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Next Steps

• The restricted stock units and stock options will vest on the earlier of the next annual meeting of the Company stockholders following June 6, 2025, or the first anniversary of the grant date (June 6, 2026).
• The non-qualified stock options can be exercised at an exercise price of $105.99 until their expiration date of June 6, 2035.

Key Dates

Keywords

Ligand Pharmaceuticals, LGND, Jason Aryeh, Form 4, SEC filing, beneficial ownership, restricted stock units, RSUs, stock options, insider transaction, director compensation, equity grant